NSRX
Nasus Pharma Ltd. (AMEX)
Healthcare — Drug Manufacturers - General
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Buy
2.0 / 5
3 analysts
$3.52
+$0.02 (+0.43%)
Target:
$19.67
(459.5%)
Sign in to add NSRX to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $41.16M |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | $-0.72 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | 4.26 |
| Recommendation | Buy 2.0 |
| Analyst Target | $19.67 |
| Analysts | 3 |
| Indexes | AMEX |
Technical Indicators
| RSI (14) | 69.5 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $9.99 |
| 52-Week Low | $1.98 |
| 50-Day Avg | $3.09 |
| 200-Day Avg | $5.32 |
| Avg Volume | 70.9K |
| Volume | 2.6K |
Performance Analysis
BULLISHNSRX shows predominantly bullish signals based on its fundamentals and technicals.
~
Trading at 19% of its 52-week range.
+
RSI at 69.5 shows positive momentum.
+
Wall Street consensus is "Buy" from 3 analysts.
+
Average analyst target of $19.67 implies 459.5% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:23 UTC
Back to Screener Export Report